Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Retinol-binding protein 7 is an endothelium-specific PPARγ cofactor mediating an antioxidant response through adiponectin
Chunyan Hu, Henry L. Keen, Ko-Ting Lu, Xuebo Liu, Jing Wu, Deborah R. Davis, Stella-Rita C. Ibeawuchi, Silke Vogel, Frederick W. Quelle, Curt D. Sigmund
Chunyan Hu, Henry L. Keen, Ko-Ting Lu, Xuebo Liu, Jing Wu, Deborah R. Davis, Stella-Rita C. Ibeawuchi, Silke Vogel, Frederick W. Quelle, Curt D. Sigmund
View: Text | PDF
Research Article Vascular biology

Retinol-binding protein 7 is an endothelium-specific PPARγ cofactor mediating an antioxidant response through adiponectin

  • Text
  • PDF
Abstract

Impaired PPARγ activity in endothelial cells causes oxidative stress and endothelial dysfunction which causes a predisposition to hypertension, but the identity of key PPARγ target genes that protect the endothelium remain unclear. Retinol-binding protein 7 (RBP7) is a PPARγ target gene that is essentially endothelium specific. Whereas RBP7-deficient mice exhibit normal endothelial function at baseline, they exhibit severe endothelial dysfunction in response to cardiovascular stressors, including high-fat diet and subpressor angiotensin II. Endothelial dysfunction was not due to differences in weight gain, impaired glucose homeostasis, or hepatosteatosis, but occurred through an oxidative stress–dependent mechanism which can be rescued by scavengers of superoxide. RNA sequencing revealed that RBP7 was required to mediate induction of a subset of PPARγ target genes by rosiglitazone in the endothelium including adiponectin. Adiponectin was selectively induced in the endothelium of control mice by high-fat diet and rosiglitazone, whereas RBP7 deficiency abolished this induction. Adiponectin inhibition caused endothelial dysfunction in control vessels, whereas adiponectin treatment of RBP7-deficient vessels improved endothelium-dependent relaxation and reduced oxidative stress. We conclude that RBP7 is required to mediate the protective effects of PPARγ in the endothelium through adiponectin, and RBP7 is an endothelium-specific PPARγ target and regulator of PPARγ activity.

Authors

Chunyan Hu, Henry L. Keen, Ko-Ting Lu, Xuebo Liu, Jing Wu, Deborah R. Davis, Stella-Rita C. Ibeawuchi, Silke Vogel, Frederick W. Quelle, Curt D. Sigmund

×

Figure 7

RBP7-mediated antioxidant protection requires adiponectin (AdipoQ).

Options: View larger image (or click on image) Download as PowerPoint
RBP7-mediated antioxidant protection requires adiponectin (AdipoQ).
(A a...
(A and B) Carotid artery from subpressor Ang-II–infused (120 ng/kg/min, 2 weeks) or vehicle-infused (isotonic saline) C57BL/6J mice were first preincubated with anti-AdipoQ antibody (5 μg/ml) or PBS in vitro for 12 hours. Vasodilation of carotid arteries was measured in response to acetylcholine (ACh) (A) and sodium nitroprusside (SNP) (B). *P < 0.05 vs. all other curves by 2-way repeated measures (RM) ANOVA. n = 6 per group. (C) Western blot showing phosphorylation of AMPKα at T172 and total AMPKα (tAMPKα) in mouse lung endothelial cells (MLECs) treated with insulin (In, 100 nM) and the indicated dose (μg/ml) of AdipoQ. (D) Vasodilation of the basilar artery from HFD-fed RBP7-deficient mice after incubation with recombinant AdipoQ (5 μg/ml, 4 hours) in vitro was measured in response to ACh. *P < 0.05 vs. all other curves by 2-way RM ANOVA. n = 5–8 per group. (E) Vasodilation of the carotid artery from subpressor Ang-II–treated RBP7-deficient and control mice after incubation with recombinant AdipoQ (5 μg/ml, 12 hours) in vitro was measured in response to ACh. *P < 0.05 vs. all other curves by 2-way RM ANOVA. n = 7 per group. Vasodilation of the carotid artery from subpressor Ang-II–treated RBP7-deficient mice after incubation with recombinant AdipoQ (5 μg/ml, 12 hours) in vitro was measured in response to ACh. Vessels were preincubated with the AMPK inhibitor compound C (5 μmol/l, F) and PKA inhibitor H89 (1 μmol/l, G) for 1 hour before AdipoQ. *P < 0.05 compound C or H89 vs. Ang-II + AdipoQ and control Ang-II by 2-way RM ANOVA. Samples sizes are n = 13 (control–Ang-II), 9 (RBP7 + Ang-II), 4 (RBP7 + Ang-II + AdipoQ), 6 (RBP7 + Ang-II + AdipoQ + compound C), 7 (RBP7 + Ang-II + AdipoQ + H89). (H and I) Representative photomicrographs of dihydroethidium (DHE) fluorescence staining of carotid arteries from HFD-fed (H) and Ang-II–treated (I) control and RBP7-deficient mice. Scale bars: 100 μm. Summary data are presented next to each set of micrographs. Results are the mean ± SEM. *P < 0.05 RBP7 vs. control; #P < 0.05 AdipoQ vs. vehicle in RBP7-deficient mice; **P < 0.05 compound C vs. AdipoQ. All analyses were by 2-way ANOVA. Sample sizes are n = 4 for the Ang-II experiment and n = 6–7 for the HFD experiment. Ang-II, angiotensin II; HFD, high-fat diet; RBP7, retinol-binding protein 7; V, vehicle.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts